Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis.

IF 2.6 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2024-09-24 DOI:10.5306/wjco.v15.i9.1177

Yan-Hong Yao, Hua Zhang, Yu Xiao, Zhen-Tao Liu, Yan-Yan Shi, Jin-Yu Yu, Qian Li, Bao-Shan Cao

{"title":"Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis.","authors":"Yan-Hong Yao, Hua Zhang, Yu Xiao, Zhen-Tao Liu, Yan-Yan Shi, Jin-Yu Yu, Qian Li, Bao-Shan Cao","doi":"10.5306/wjco.v15.i9.1177","DOIUrl":null,"url":null,"abstract":"Background: Hemorrhage, which is not a rare complication in patients with gastric cancer (GC)/gastroesophageal junction cancer (GEJC), can lead to a poor prognosis. However, no study has examined the effectiveness and safety of chemotherapy as an initial therapy for GC/GEJC patients with overt bleeding (OB).Aim: To investigate the impact of OB on the survival and treatment-related adverse events (TRAEs) of GC/GEJC patients.Methods: Patients with advanced or metastatic GC/GEJC who received systematic treatment at Peking University Third Hospital were enrolled in this study. Propensity score matching (PSM) analysis was performed.Results: After 1:2 PSM analysis, 93 patients were assessed, including 32 patients with OB before treatment (OBBT) and 61 patients without OBBT. The disease control rate was 90.6% in the group with OBBT and 88.5% in the group without OBBT, and this difference was not statistically significant. There was no difference in the incidence of TRAEs between the group with OBBT and the group without OBBT. The median overall survival (mOS) was 15.2 months for patients with OBBT and 23.7 months for those without OBBT [hazard ratio (HR) = 1.101, 95% confidence interval (CI): 0.672-1.804, log rank P = 0.701]. The mOS was worse for patients with OB after treatment (OBAT) than for those without OBAT (11.4 months vs 23.7 months, HR = 1.787, 95%CI: 1.006-3.175, log rank P = 0.044).Conclusion: The mOS for GC/GEJC patients with OBBT was similar to that for those without OBBT, but the mOS for patients with OBAT was worse than that for those without OBAT.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438845/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v15.i9.1177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hemorrhage, which is not a rare complication in patients with gastric cancer (GC)/gastroesophageal junction cancer (GEJC), can lead to a poor prognosis. However, no study has examined the effectiveness and safety of chemotherapy as an initial therapy for GC/GEJC patients with overt bleeding (OB).

Aim: To investigate the impact of OB on the survival and treatment-related adverse events (TRAEs) of GC/GEJC patients.

Methods: Patients with advanced or metastatic GC/GEJC who received systematic treatment at Peking University Third Hospital were enrolled in this study. Propensity score matching (PSM) analysis was performed.

Results: After 1:2 PSM analysis, 93 patients were assessed, including 32 patients with OB before treatment (OBBT) and 61 patients without OBBT. The disease control rate was 90.6% in the group with OBBT and 88.5% in the group without OBBT, and this difference was not statistically significant. There was no difference in the incidence of TRAEs between the group with OBBT and the group without OBBT. The median overall survival (mOS) was 15.2 months for patients with OBBT and 23.7 months for those without OBBT [hazard ratio (HR) = 1.101, 95% confidence interval (CI): 0.672-1.804, log rank P = 0.701]. The mOS was worse for patients with OB after treatment (OBAT) than for those without OBAT (11.4 months vs 23.7 months, HR = 1.787, 95%CI: 1.006-3.175, log rank P = 0.044).

Conclusion: The mOS for GC/GEJC patients with OBBT was similar to that for those without OBBT, but the mOS for patients with OBAT was worse than that for those without OBAT.

查看原文本刊更多论文

对明显出血的胃癌患者进行系统治疗：倾向得分匹配分析

背景：出血在胃癌（GC）/胃食管交界处癌（GEJC）患者中并非罕见的并发症，可导致不良预后。然而，还没有研究对化疗作为胃癌/胃食管交界处癌患者明显出血（OB）的初始治疗的有效性和安全性进行调查。目的：调查OB对胃癌/胃食管交界处癌患者的生存和治疗相关不良事件（TRAEs）的影响：方法：纳入在北京大学第三医院接受系统治疗的晚期或转移性 GC/GEJC 患者。结果：经过 1:2 的倾向评分匹配（PSM）分析后，GC/GEJC 患者的平均病死率为 1：2：经过 1:2 PSM 分析，共评估了 93 例患者，其中 32 例患者在治疗前进行了 OBT（OBBT），61 例患者未进行 OBBT。接受 OBBT 治疗组的疾病控制率为 90.6%，未接受 OBBT 治疗组的疾病控制率为 88.5%，差异无统计学意义。在TRAE的发生率方面，接受OBBT治疗组和未接受OBBT治疗组之间没有差异。接受OBBT治疗的患者的中位总生存期（mOS）为15.2个月，未接受OBBT治疗的患者为23.7个月[危险比（HR）=1.101，95%置信区间（CI）：0.672-1.804，对数秩P=0.701]。治疗后有 OB（OBAT）的患者的 mOS 比没有 OBAT 的患者差（11.4 个月 vs 23.7 个月，HR = 1.787，95%CI：1.006-3.175，对数秩 P = 0.044）：结论：接受OBBT治疗的GC/GEJC患者的mOS与未接受OBBT治疗的患者相似，但接受OBAT治疗的患者的mOS比未接受OBAT治疗的患者差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.